French startup Iktos has secured €15.5 million in Collection A funding for its AI-powered drug discovery platform.
The spherical was co-led by M Ventures and Debiopharm Innovation Fund, with participation from Omnes Capital, and can allow Iktos to develop its expertise additional and broaden its SaaS software program providing. The corporate is ready to launch Robotics, an end-to-end drug discovery platform that makes use of AI and automation of chemical synthesis to speed up drug discovery timelines.
Moreover, the corporate will broaden its utility of options to organic merchandise, permitting it to supply absolutely built-in drug discovery providers to the pharmaceutical business.
Iktos, which was based in 2016, makes use of a expertise platform for deep learning-based drug design that provides vital productiveness good points in upstream pharmaceutical R&D. The platform is obtainable as skilled providers and SaaS software program Makya, and Spaya, a synthesis planning software program based mostly on Iktos’ proprietary AI expertise for retrosynthesis. Its AI options will speed up drug discovery whereas rising the probability of drug candidates reaching medical growth, with collaborations already in place with Janssen, Merck, Pfizer, Servier, Ono, and Teijin.
Based on Yann Gaston-Mathé, the President and co-founder of Iktos, “The applying of synthetic intelligence to early drug discovery and design presents the potential of a radical change for researchers exploring such a chemical universe. The applied sciences now we have developed have been enabling a number of companions in realizing this promise. We welcome our new, skilled, investor syndicate and recent financing that may permit us to execute our plan of being the popular associate for the business to deal with their drug growth wants.”
In the meantime, Dr. Nadiya Ishnazarova of M Ventures said, “We imagine Iktos with its mature expertise throughout generative AI and synthesis planning, and developments in constructing absolutely built-in drug discovery platform has the potential to supply a aggressive edge for the pharma business as AI/ML turns into a core function of R&D.”
Tanja Dowe, CEO of Debiopharm Innovation Fund added, “We’re very excited to collaborate with a formidable syndicate of robust buyers M Ventures and Omnes Capital to assist Iktos in executing its plans to develop cutting-edge end-to-end AIDD capabilities.”
The funding spherical will allow Iktos to proceed to be a most well-liked associate for the pharmaceutical business, and the launch of Robotics will allow the corporate to turn into one of many first to supply absolutely built-in drug discovery providers to the sector. With vital advantages already acknowledged in its AI options, Iktos is poised to play a number one function within the AI-powered drug discovery revolution.
